micro-community-banner
Profile Image
  • Add Media
  • Saved

3d

Did you know? Childhood obesity disrupts multiple endocrine pathways, leading to insulin resistance, hormonal imbalances, and increased risk of early-onset metabolic and cardiovascular complications. These changes can also impact growth, puberty, and long-term health trajectories.

Could early endocrine-focused interventions in obesity help prevent long-term metabolic and cardiovascular disease progression?

NCCN Guidelines

Could early endocrine-focused interventions in obesity help prevent long-term metabolic and cardiovascular disease progression?

Profile Image
  • Saved

4d
Obesity accelerates cardiovascular ageing - PubMed

Obesity accelerates cardiovascular ageing - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/40197620/

A global obesity pandemic, coupled with an increasingly ageing population, is exacerbating the burden of cardiovascular disease. Indeed, clinical and experimental evidence underscores a potential connection between obesity and ageing...

Obesity accelerates cardiovascular aging through shared mechanisms like inflammation and mitochondrial dysfunction; weight reduction and metabolic therapies may counteract these processes, reducing cardiovascular disease risk and improving longevity.

Profile Image
  • Saved

5d
Integrating oral GLP-1 pathways into obesity care: clinical decisions beyond initiation

As obesity care continues to evolve, clinical focus is shifting from initiating therapy to managing obesity as a long-term, relapsing condition. Recent advances in oral glucagon-like peptide-1 (GLP-1) receptor agonist development reinforce this shift, prompting clinicians to consider not only whether to use pharmacologic therapy, but how it can be integrated into sustained, multidimensional care plans over time.

GLP-1 receptor activation influences appetite regulation, satiety signaling, and metabolic pathways central to obesity pathophysiology. Oral formulations demonstrate that these mechanisms can be engaged through daily administration, expanding how clinicians think about treatment design and long-term engagement. This evolution brings renewed attention to clinical integration—how pharmacologic therapy aligns with behavioral strategies, lifestyle interventions, and ongoing monitoring rather than functioning as a stand-alone solution.

Patient selection and adherence remain central considerations in long-term obesity management. Functional factors such as daily dosing routines, gastrointestinal tolerability, and treatment fatigue—as well as emotional factors including expectations, motivation, and prior weight-loss experiences—may influence sustained use and outcomes. These considerations highlight the importance of shared decision-making and regular reassessment as patient needs and priorities evolve.

Rather than viewing therapy choice as a single decision point, many clinicians are approaching obesity care as a dynamic process that requires adjustment over time. Evidence-based strategies increasingly emphasize structured follow-up, realistic goal-setting, behavioral support, and coordinated, multidisciplinary care. Within this framework, oral GLP-1 approaches may offer flexibility across different phases of treatment, including escalation, stabilization, or maintenance.

What factors most influence how you select patients for long-term pharmacologic obesity therapy?As oral GLP-1 options enter clinical practice, what adherence challenges or integration considerations will most shape how you incorporate them into comprehensive obesity care?

Profile Image
  • 5d
    GLP-1 therapy is good for obese PT’s. I am concerned about the long term side effects. There have been some reports on the news media about weakness in the lower Show More
  • 1w
    the need, so bmi in overweight/obesity/morbidly obese range and the tolerability and affordability of the medication again side effects and effective weight loss are all clinical factors that play a role Show More

Show More Comments

  • Saved

1w
Background Image DesktopBackground Image Mobile

Obesity-related TyG indices, reflecting insulin resistance, were linked to higher risk of retinal arteriosclerosis. Findings highlight how metabolic dysfunction and poor cardiovascular health contribute to early microvascular injury, reinforcing the need for integrated risk assessment.

Assess metabolic risk beyond BMI

Profile Image
  • Saved

1w
Lipodystrophy: an uncommon cause of insulin resistance and young-onset diabetes - PubMed

Lipodystrophy: an uncommon cause of insulin resistance and young-onset diabetes - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/41948357/

Insulin resistance due to lipodystrophy syndromes is an uncommon but important cause of diabetes. It is often overlooked due to limited awareness. Standard glucose-lowering therapies often fail to achieve durable...

Lipodystrophy is a rare cause of insulin resistance and early diabetes, often misdiagnosed. Genetic causes like SHORT syndrome should be suspected in lean patients with atypical features and poor response to standard therapies.

Profile Image